相关实验视频

Updated: Jun 23, 2025

HUVEC Tube-formation Assay to Evaluate the Impact of Natural Products on Angiogenesis

HUVEC Tube-formation Assay to Evaluate the Impact of Natural Products on Angiogenesis

Published on: June 24, 2019

自然药物在类风湿性关节炎中的保护作用通过抑制血管生成

Chang Gao¹, Xiao-Di Song², Fang-Hui Chen¹

¹Department of Pharmacy, First Affiliated Hospital of Gannan Medical University, Jiangxi, Ganzhou, China.

Frontiers in pharmacology

|June 17, 2024

概括

天然药物可以抑制血管生成,这是类风湿性关节炎 (RA) 关节破坏的关键因素. 这些疗法准了参与RA的途径,通过阻断突血管生成提供了新的治疗选择.

科学领域:

类风湿病学类风湿病学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

类风湿性关节炎 (RA) 是一种慢性免疫性疾病,导致骨和关节的逐渐破坏.
由血管新生驱动的突性增生和炎症是RA关节损伤的核心原因.
针对突血管生成是 RA 治疗的关键策略.

研究的目的:

讨论影响RA血管生成的因素.
系统地总结抑制血管生成的天然药物.
审查这些天然药物的抗血管生成机制,以治疗RA.

主要方法:

关于天然药物的文献综述及其对RA血管生成的影响.
通过天然药物调节的信号通路的分析 (例如,HIF/VEGF/ANG,PI3K/Akt,MAPKs,NF-κB,PPARγ,JAK2/STAT3).
识别关键的自然产品,如Tripterygium wilfordii . f. (TwHF),sinomenine,以及Paeonia lactiflora Pall. 的总葡萄糖体.

主要成果:

自然药物表现出明显的抑制作用,对状血管生成.
这些药物调节了血管生成至关重要的多种信号通路.
三体威尔福迪. f. ,sinomenine,以及Paeonia lactiflora Pall. 这两种类型的植物. 这些都是突出的例子.

结论:

自然药物提供了一个有希望的方法来管理RA通过向血管生成.
了解它们的机制为RA提供了新的治疗视角.
这些天然产品的进一步开发可能会导致新的RA治疗方法.

关键词:

在VEGF中,VEGF是VEGF.血管新生是因为血管新生.配料配料配料配料这些机制的机制.天然药物天然药物类风湿性关节炎是一种类风湿性关节炎.

更多相关视频

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

相关概念视频

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...